GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

This trial is testing a new investigational drug called GI-101 (or GI-101A) — either alone or combined with immunotherapy or targeted therapy — in people with advanced solid tumors. GI-101 is designed to both stimulate immune cells and block tumor immune-evasion signals at the same time. **You may be eligible if...** - You are 18 or older with an advanced solid tumor - Your cancer is measurable on scans - You are in good overall health (ECOG 0–1) - Previous treatment side effects have mostly resolved - If HIV-positive, your infection is well-controlled on treatment **You may NOT be eligible if...** - Your cancer has spread to the brain or brain lining - You have an active second cancer - You have active hepatitis B, hepatitis C, or tuberculosis - You have an autoimmune disease requiring treatment in the past 2 years - You have a history of immune deficiency or are on immune-suppressing medicines Talk to your doctor to see if this trial is right for you.